Cargando…

From strain engineering to process development: monoclonal antibody production with an unnatural amino acid in Pichia pastoris

BACKGROUND: Expansion of the genetic code is a frequently employed approach for the modification of recombinant protein properties. It involves reassignment of a codon to another, e.g., unnatural, amino acid and requires the action of a pair of orthogonal tRNA and aminoacyl tRNA synthetase modified...

Descripción completa

Detalles Bibliográficos
Autores principales: Tir, Nora, Heistinger, Lina, Grünwald-Gruber, Clemens, Jakob, Leo A., Dickgiesser, Stephan, Rasche, Nicolas, Mattanovich, Diethard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367057/
https://www.ncbi.nlm.nih.gov/pubmed/35953849
http://dx.doi.org/10.1186/s12934-022-01882-6
_version_ 1784765705093120000
author Tir, Nora
Heistinger, Lina
Grünwald-Gruber, Clemens
Jakob, Leo A.
Dickgiesser, Stephan
Rasche, Nicolas
Mattanovich, Diethard
author_facet Tir, Nora
Heistinger, Lina
Grünwald-Gruber, Clemens
Jakob, Leo A.
Dickgiesser, Stephan
Rasche, Nicolas
Mattanovich, Diethard
author_sort Tir, Nora
collection PubMed
description BACKGROUND: Expansion of the genetic code is a frequently employed approach for the modification of recombinant protein properties. It involves reassignment of a codon to another, e.g., unnatural, amino acid and requires the action of a pair of orthogonal tRNA and aminoacyl tRNA synthetase modified to recognize only the desired amino acid. This approach was applied for the production of trastuzumab IgG carrying p-azido-l-phenylalanine (pAzF) in the industrial yeast Pichia pastoris. Combining the knowledge of protein folding and secretion with bioreactor cultivations, the aim of the work was to make the production of monoclonal antibodies with an expanded genetic code cost-effective on a laboratory scale. RESULTS: Co-translational transport of proteins into the endoplasmic reticulum through secretion signal prepeptide change and overexpression of lumenal chaperones Kar2p and Lhs1p improved the production of trastuzumab IgG and its Fab fragment with incorporated pAzF. In the case of Fab, a knockout of vacuolar targeting for protein degradation further increased protein yield. Fed-batch bioreactor cultivations of engineered P. pastoris strains increased IgG and IgG(pAzF) productivity by around 50- and 20-fold compared to screenings, yielding up to 238 mg L(−1) and 15 mg L(−1) of fully assembled tetrameric protein, respectively. Successful site-specific incorporation of pAzF was confirmed by mass spectrometry. CONCLUSIONS: Pichia pastoris was successfully employed for cost-effective laboratory-scale production of a monoclonal antibody with an unnatural amino acid. Applying the results of this work in glycoengineered strains, and taking further steps in process development opens great possibilities for utilizing P. pastoris in the development of antibodies for subsequent conjugations with, e.g., bioactive payloads. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12934-022-01882-6.
format Online
Article
Text
id pubmed-9367057
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93670572022-08-12 From strain engineering to process development: monoclonal antibody production with an unnatural amino acid in Pichia pastoris Tir, Nora Heistinger, Lina Grünwald-Gruber, Clemens Jakob, Leo A. Dickgiesser, Stephan Rasche, Nicolas Mattanovich, Diethard Microb Cell Fact Research BACKGROUND: Expansion of the genetic code is a frequently employed approach for the modification of recombinant protein properties. It involves reassignment of a codon to another, e.g., unnatural, amino acid and requires the action of a pair of orthogonal tRNA and aminoacyl tRNA synthetase modified to recognize only the desired amino acid. This approach was applied for the production of trastuzumab IgG carrying p-azido-l-phenylalanine (pAzF) in the industrial yeast Pichia pastoris. Combining the knowledge of protein folding and secretion with bioreactor cultivations, the aim of the work was to make the production of monoclonal antibodies with an expanded genetic code cost-effective on a laboratory scale. RESULTS: Co-translational transport of proteins into the endoplasmic reticulum through secretion signal prepeptide change and overexpression of lumenal chaperones Kar2p and Lhs1p improved the production of trastuzumab IgG and its Fab fragment with incorporated pAzF. In the case of Fab, a knockout of vacuolar targeting for protein degradation further increased protein yield. Fed-batch bioreactor cultivations of engineered P. pastoris strains increased IgG and IgG(pAzF) productivity by around 50- and 20-fold compared to screenings, yielding up to 238 mg L(−1) and 15 mg L(−1) of fully assembled tetrameric protein, respectively. Successful site-specific incorporation of pAzF was confirmed by mass spectrometry. CONCLUSIONS: Pichia pastoris was successfully employed for cost-effective laboratory-scale production of a monoclonal antibody with an unnatural amino acid. Applying the results of this work in glycoengineered strains, and taking further steps in process development opens great possibilities for utilizing P. pastoris in the development of antibodies for subsequent conjugations with, e.g., bioactive payloads. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12934-022-01882-6. BioMed Central 2022-08-11 /pmc/articles/PMC9367057/ /pubmed/35953849 http://dx.doi.org/10.1186/s12934-022-01882-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Tir, Nora
Heistinger, Lina
Grünwald-Gruber, Clemens
Jakob, Leo A.
Dickgiesser, Stephan
Rasche, Nicolas
Mattanovich, Diethard
From strain engineering to process development: monoclonal antibody production with an unnatural amino acid in Pichia pastoris
title From strain engineering to process development: monoclonal antibody production with an unnatural amino acid in Pichia pastoris
title_full From strain engineering to process development: monoclonal antibody production with an unnatural amino acid in Pichia pastoris
title_fullStr From strain engineering to process development: monoclonal antibody production with an unnatural amino acid in Pichia pastoris
title_full_unstemmed From strain engineering to process development: monoclonal antibody production with an unnatural amino acid in Pichia pastoris
title_short From strain engineering to process development: monoclonal antibody production with an unnatural amino acid in Pichia pastoris
title_sort from strain engineering to process development: monoclonal antibody production with an unnatural amino acid in pichia pastoris
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367057/
https://www.ncbi.nlm.nih.gov/pubmed/35953849
http://dx.doi.org/10.1186/s12934-022-01882-6
work_keys_str_mv AT tirnora fromstrainengineeringtoprocessdevelopmentmonoclonalantibodyproductionwithanunnaturalaminoacidinpichiapastoris
AT heistingerlina fromstrainengineeringtoprocessdevelopmentmonoclonalantibodyproductionwithanunnaturalaminoacidinpichiapastoris
AT grunwaldgruberclemens fromstrainengineeringtoprocessdevelopmentmonoclonalantibodyproductionwithanunnaturalaminoacidinpichiapastoris
AT jakobleoa fromstrainengineeringtoprocessdevelopmentmonoclonalantibodyproductionwithanunnaturalaminoacidinpichiapastoris
AT dickgiesserstephan fromstrainengineeringtoprocessdevelopmentmonoclonalantibodyproductionwithanunnaturalaminoacidinpichiapastoris
AT raschenicolas fromstrainengineeringtoprocessdevelopmentmonoclonalantibodyproductionwithanunnaturalaminoacidinpichiapastoris
AT mattanovichdiethard fromstrainengineeringtoprocessdevelopmentmonoclonalantibodyproductionwithanunnaturalaminoacidinpichiapastoris